Payment overview · 2025
General Payments
$241.19
11 reported records · 3 companies
Healthcare provider profile · identity verified
David J Janicki, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TERRE HAUTE, IN · NPI 1336113638
Verified facts
What the public records show
CMS Open Payments records show David J Janicki, MD received $241.19 in general payments during 2025 across 11 reported records.
Amgen Inc. accounted for 70.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $170.67 | 70.8% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.32 | 17.6% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $28.20 | 11.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $241.19 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $170.67 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.17 | 6 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $28.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 227 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 219 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 208 | 28 |
| Gabapentin | Gabapentin | 203 | 30 |
| Simvastatin | Simvastatin | 168 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 140 | 41 |
| Tramadol Hcl | Tramadol Hcl | 128 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 117 | 37 |
| Omeprazole | Omeprazole | 116 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 26 |
| Metformin Hcl | Metformin Hcl | 99 | 28 |
| Lisinopril | Lisinopril | 97 | 37 |
| Potassium Chloride | Potassium Chloride | 93 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 23 |
| Lorazepam | Lorazepam | 69 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 15 |
| Allopurinol | Allopurinol | 67 | 14 |
| Ozempic | Semaglutide | 64 | suppressed |
| Januvia | Sitagliptin Phosphate | 54 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | suppressed |
| Furosemide | Furosemide | 53 | 23 |
| Finasteride | Finasteride | 51 | suppressed |
| Pregabalin | Pregabalin | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 15 |
| Losartan Potassium | Losartan Potassium | 46 | 13 |
| Doxepin Hcl | Doxepin Hcl | 44 | suppressed |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 11 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 24 |
| Ramipril | Ramipril | 31 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Lasix | Furosemide | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $241.19 · 11 records | Amgen Inc. | OTEZLA, Ozempic, REPATHA, Rybelsus, UZEDY, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error